Northwestern Medicine scientists have discovered the genetic driver of a rare and lethal childhood leukaemia and identified a targeted molecular therapy that halts the proliferation of leukaemia cells.

The finding also has implications for treating other types of cancer.

Mixed lineage leukaemia (MLL) primarily strikes newborns and infants.

Less than 10 to 20 percent of those children (300 cases are seen in the United States per year) live no more than five years after being diagnosed.

"We've spent the last 20 years in my laboratory trying to molecularly understand how MLL translocations cause this rare and devastating form of leukaemia in children so that we can use this information to develop an effective therapy for this cancer," said lead investigator Ali Shilatifard.

"Now we've made a fundamentally important breakthrough."

The paper was published Jan. 5 in the journal Cell.

Shilatifard, the chair and professor of biochemistry and molecular genetics and professor of paediatrics, his graduate student Kevin Liang and their colleagues at Northwestern University Feinberg School of Medicine are extremely hopeful about this breakthrough and are in the process of pushing their findings into clinic for the treatment of childhood leukaemia.

Shilatifard also is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

"Mixed lineage leukaemia is caused when an errant chromosome 11 on the MLL gene breaks and attaches to other chromosomes such as chromosome 19, where it doesn't belong," said Liang, the paper's first author.

"The mutation produces a protein that drives the pathogenesis of leukaemia."

Most research related to this cancer has focused on the errant version of chromosome 11.

But there are two copies of chromosome 11, and the Shilatifard group wanted to investigate the wild-type version.

Shilatifard's laboratory discovered that individual cells with the paediatric leukaemia had extremely low levels of a protein produced by the wild-type MLL gene.

Shilatifard and Liang reasoned if they could beef up the levels of the wild-type MLL protein, it would displace the mutated version that drives cancer, and it could cure leukaemia.

Through their detailed molecular and biochemical screens, Shilatifard's lab identified a compound that stabilised the wild-type MLL and interfered with the mutant protein driving leukaemia.

To test its effectiveness, in collaboration with John Crispino's lab of Northwestern University and his fellow Andrew Volk, they grew mixed lineage leukaemia cells in a culture and transplanted them into mice.

They then injected the therapeutic compound into the mice.

The result: the wild-type MLL bounced back to healthy levels, and the leukaemia cells were not able to grow as rapidly.

Northwestern scientists are now synthesising better compounds and hope to eventually launch a Phase I trial to test these compounds in Chicago.

Source: Northwestern University